AirSculpt expects 2026 revenue of $151M-$157M while targeting net debt leverage below 2.5x

Earnings Call Insights: AirSculpt Technologies (AIRS) Q4 2025

MANAGEMENT VIEW

* CEO Yogesh Jashnani said 2025 was “a year of rebuilding and transformation,” citing added talent, new processes, a new go-to-market strategy, and “strategically exited our only clinic outside of North America to streamline operations,” while also “issuing equity and utilizing our ATM to meaningfully reduce our net debt.”
* CEO Yogesh Jashnani tied recent demand improvement to operational changes, saying the company “returned the business to stabilization and beginning in February inflected to positive same-store sales growth,” adding that “we expect Q1 same-store sales to be flat.”
* CEO Yogesh Jashnani emphasized GLP-1-related demand as a growth vector, saying GLP-1s are driving demand for “skin tightening, contour restoration and overall reshaping after weight loss,” and that skin tightening and fat removal represent “a $100 million-plus sales opportunity long term.”
* CEO Yogesh Jashnani highlighted early scaling of skin removal, stating, “Just in Q4 2025, we have completed more than 100 skin removal surgeries, and we expect this to ramp in 2026 as we expand this capability across all locations.”
* CEO Yogesh Jashnani described marketing changes that began in Q4, including “connected TV,” increased influencer engagement, and website conversion improvements, and said improved financing options are being used “while maintaining our policy of full upfront payment.”
* Quote (Chief Financial Officer Michael Arthur) “During the close process, we identified a reconciliation matter related to intercompany transactions, which led us to conduct a broader review of certain accounting treatments, including lease accounting under ASC 842.”

OUTLOOK

* Management guided fiscal 2026 revenue to $151 million to $157 million and fiscal 2026 adjusted EBITDA to $15 million to $17 million.
* CFO Michael Arthur described pacing and comparability factors, saying “we expect the business to build momentum as the year progresses,” and that the midpoint of the revenue range reflects “approximately 3% comparable growth, excluding London from 2025,” while noting “our London center contributed 1% to comps in 2025.”
* CFO Michael Arthur said guidance assumes no new center openings: “our guidance does not contemplate any openings this year as we continue to focus our efforts and resources on revenue growth in our existing base.”

FINANCIAL RESULTS

* CFO Michael Arthur reported Q4 revenue of $33.4 million, “down approximately 15% versus the prior year quarter,” with “same-store revenue… declined 16%,” and said the decline reflected “lower case volume amidst a challenging consumer spending environment.”
* CFO Michael Arthur said cost actions supported profitability, reporting cost of services of $13.7 million and gross margin “roughly 2%… to approximately 59%,” while SG&A was “approximately $18.2 million,” down “approximately $5 million” year-over-year.
* CFO Michael Arthur reported adjusted EBITDA of $2.5 million (7.4% margin), and noted customer acquisition cost was “roughly $3,300 per case,” with “approximately 50%” of patients using financing while the company “received full payment for all procedures upfront.”
* CFO Michael Arthur reported full-year revenue of $151.8 million and full-year adjusted EBITDA of “approximately $15 million” (about 10% margin), and said cash flow from operations was $3.1 million.
* CFO Michael Arthur said year-end liquidity and leverage improved, reporting cash of $8.4 million and gross debt of $56 million as of December 31, 2025, adding the company raised $14.8 million via the ATM in Q1 and “paid down an additional $11 million of debt principal,” while targeting refinancing and “a net debt leverage ratio below 2.5x.”
* CFO Michael Arthur attributed the 10-K delay to accounting review items and said changes were immaterial to operations: “This had no impact to revenue, cash or our day-to-day operations, and we remain fully compliant with our bank covenants.”

Q&A

* Joshua Raskin, Nephron Research: asked why Q1 revenue guidance implies a slight year-over-year decline while full-year 2026 rises and whether seasonality is more back-end loaded; CEO Jashnani responded, “we are being measured in how we guide,” citing comps moving “to positive comps” and adding the company is “focused on execution at the moment.”
* Joshua Raskin, Nephron Research: asked whether the company can isolate core body sculpting trends outside GLP-1-related procedures; CEO Jashnani answered that “the core business around body contouring and fat removal is holding relatively steady,” while calling GLP-1s “the next wave of that change.”
* Sam Eiber, BTIG: asked about early feedback from the excisional/skin removal pilot and how it informs broader rollout; CEO Jashnani said “early signs are very encouraging,” surgeons are “comfortable with,” and the company plans to “ramp it up” while reviewing outcomes over time.
* Sam Eiber, BTIG: asked about capital allocation and debt paydown versus comfort at ~2.5x leverage; CFO Arthur said the “#1 priority still is to get the balance sheet in a healthy position,” the company is “looking to refinance the debt,” and capital allocation remains focused on “investing back into the business… on sales and marketing” and later “new de novos.”

SENTIMENT ANALYSIS

* Analysts’ tone was neutral to slightly skeptical, pressing for clarity on guidance phasing and sustainability of growth drivers, reflected in questions about why revenue is “more back-end loaded this year” and how to isolate “market-like trends” in the core business.
* Management’s tone was slightly positive but measured, emphasizing stabilization and execution discipline, including CEO Jashnani’s “we are being measured in how we guide,” alongside comments that trends “improved meaningfully.”
* Compared with the prior quarter, the current call sounded more execution-focused and operationally specific, shifting from Q3’s “timing instead of trajectory” framing to Q4’s emphasis on stabilization, marketing changes already underway, and formal 2026 revenue/EBITDA ranges.

QUARTER-OVER-QUARTER COMPARISON

* Q4 added a formal fiscal 2026 outlook (revenue $151 million to $157 million; adjusted EBITDA $15 million to $17 million), whereas Q3 centered on an updated fiscal 2025 outlook and discussed Q4 improving trends without providing 2026 guidance.
* Q4 expanded detail on the GLP-1 procedure roadmap, with CEO Jashnani disclosing “more than 100 skin removal surgeries” in Q4 and plans to expand across locations, while Q3 emphasized pilots and the need for “a suite of procedures” beyond stand-alone tightening.
* Q4 reflected leadership transition completion, with Michael Arthur speaking on his “first conference call as CFO,” while Q3 announced he would join in January 2026 and that Dennis Dean would retire.
* Q4 introduced a reporting/process overhang (10-K delay tied to intercompany reconciliation and ASC 842 review) that was not a focus of Q3’s narrative.

RISKS AND CONCERNS

* CFO Michael Arthur warned of supply disruption risk for helium plasma used in skin tightening: “a meaningful portion of the global supply is currently offline due to the Iran conflict,” adding, “We are monitoring the situation closely, and we will manage the business accordingly.”
* Management continued to cite demand sensitivity, with CFO Arthur describing a “challenging consumer spending environment” affecting case volumes.
* CFO Arthur said the accounting review and resulting prior-year adjustments “had no impact to revenue, cash or our day-to-day operations,” while also stating, “We recognize these issues should have been identified earlier,” and that the company is “taking steps to strengthen our financial processes and controls going forward.”

FINAL TAKEAWAY

Management framed Q4 as a pivot from a 2025 “rebuilding and transformation” year toward early 2026 stabilization, highlighting positive same-store sales in February, an expanded GLP-1-driven procedure set led by skin tightening and skin removal (with more than 100 Q4 skin removal surgeries), and a 2026 plan centered on revenue of $151 million to $157 million and adjusted EBITDA of $15 million to $17 million. The call also emphasized balance-sheet priorities (including refinancing intentions and a net leverage target below 2.5x), no de novo openings in 2026 guidance, and monitoring of helium plasma supply risk, alongside an explanation for the delayed 10-K tied to intercompany reconciliation and ASC 842 review.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/airs/earnings/transcripts]

MORE ON AIRSCULPT TECHNOLOGIES

* AirSculpt Technologies, Inc. (AIRS) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4888091-airsculpt-technologies-inc-airs-q4-2025-earnings-call-transcript]
* AirSculpt Technologies: Cheap Enough Valuation Warrants Buy Rating [https://seekingalpha.com/article/4883656-airsculpt-technologies-cheap-enough-valuation-warrants-buy-rating]
* Seeking Alpha’s Quant Rating on AirSculpt Technologies [https://seekingalpha.com/symbol/AIRS/ratings/quant-ratings]
* Historical earnings data for AirSculpt Technologies [https://seekingalpha.com/symbol/AIRS/earnings]
* Financial information for AirSculpt Technologies [https://seekingalpha.com/symbol/AIRS/income-statement]